Skip to main content

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

Investigació translacional en càncer infantil (GRE)

IP: Josep Sánchez de Toledo Codina
Collaborators: Investigació translacional en càncer infantil (GRE) , Aroa Soriano Fernández, Maria Cristina Díaz de Heredia Rubio, Miguel Segura Ginard, Anna Llort Sales, Raquel Hladun Alvaro, Ariadna Boloix Amenós, Laura Alonso Garcia, Josep Roma Castanyer
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 30000
Reference: 2014 SGR 660
Duration: 01/01/2014 - 31/12/2016

Nanoterapia basada en microRNAs: nuevo tratamiento para tumores pediátricos del sistema nervioso

IP: Miguel Segura Ginard
Collaborators: Luís Gros Subias, Aroa Soriano Fernández, Josep Sánchez de Toledo Codina, Constantino Sábado Álvarez
Funding agency: Instituto de Salud Carlos III
Funding: 116765
Reference: PI14/00561
Duration: 01/01/2015 - 31/12/2017

TERAPIA PERSONALIZADA CONTRA ERK5 EN NEUROBLASTOMA

IP: Aroa Soriano Fernández
Collaborators: Miguel Segura Ginard
Funding agency: Asociación Española Contra el Cáncer
Funding: 20000
Reference: 2014/AECC-JB/SORIANO
Duration: 31/01/2015 - 31/01/2017

Red Temática de Investigación Cooperativa en Cáncer - RTICC

IP: Josep Sánchez de Toledo Codina
Collaborators: Red Temática de Investigación Cooperativa en Cáncer - RTICC, Luís Gros Subias, Pablo Velasco Puyó, Aroa Soriano Fernández, Maria Cristina Díaz de Heredia Rubio, Miguel Segura Ginard, Constantino Sábado Álvarez, Anna Llort Sales, Laura Alonso Garcia, Josep Roma Castanyer
Funding agency: Instituto de Salud Carlos III
Funding: 186750
Reference: RD12/0036/0016
Duration: 01/01/2013 - 30/06/2017

Related news

"Generation of a bank of surgical orthotopic PDX (patient-derived xenografts) models within the framework of a personalized medicine program in pediatric cancer" was the awarded work, of the Childhood Cancer and Hematological Diseases Group of VHIR.

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Related professionals

Mireia Benito Jimenez

Mireia Benito Jimenez

Research assistant
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more
Margot Noemi Costa Gutiérrez

Margot Noemi Costa Gutiérrez

Administrative
General Services and Infrastructures Unit
Manager
Read more
Yasmine Margaret Baktash

Yasmine Margaret Baktash

Postdoctoral researcher
Infectious Diseases
Read more
Elba Agusti Rovira

Elba Agusti Rovira

Research technician
Donation and transplantation of organs, tissues and cells
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.